Evidence map›Paper›PMID 34944022›Full record

ArticleCells2021

NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression.

David Mengel, Tze How Mok, Akin Nihat, Wen Liu, Robert A Rissman, Douglas Galasko, Henrik Zetterberg, Simon Mead, John Collinge, Dominic M Walsh

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Plasma N-terminal tau fragment is an amyloid-dependent biomarker in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  6. Review
  7. Tau and Amyloid β Protein in Patient-Derived Aqueous Brain Extracts Act Concomitantly to Disrupt Long-Term PotentiationThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
  8. All the Tau We Cannot See.Annual review of medicine · 2023
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 8 institutions in 4 countries.

David MengelLaboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Tze How MokMRC Prion Unit at UCL, UCL Institute of Prion Diseases and NHS National Prion Clinic, National Hospital for Neurology and Neurosurgery, UCL Hospitals NHS Foundation Trust, London W1W 7FF, UK.
Akin NihatMRC Prion Unit at UCL, UCL Institute of Prion Diseases and NHS National Prion Clinic, National Hospital for Neurology and Neurosurgery, UCL Hospitals NHS Foundation Trust, London W1W 7FF, UK.
Wen LiuLaboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Robert A RissmanDepartment of Neurosciences, University of California San Diego, La Jolla, CA 92093, USA.
Douglas GalaskoVA San Diego Healthcare System, La Jolla, CA 92161, USA.
Henrik ZetterbergDepartment of Neurodegenerative Disease, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK.
Simon MeadMRC Prion Unit at UCL, UCL Institute of Prion Diseases and NHS National Prion Clinic, National Hospital for Neurology and Neurosurgery, UCL Hospitals NHS Foundation Trust, London W1W 7FF, UK.
John CollingeMRC Prion Unit at UCL, UCL Institute of Prion Diseases and NHS National Prion Clinic, National Hospital for Neurology and Neurosurgery, UCL Hospitals NHS Foundation Trust, London W1W 7FF, UK.
Dominic M WalshLaboratory for Neurodegenerative Research, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Brigham and Women's Hospital · USUniversity College London · GBHarvard University · USMRC Prion Unit · GBNational Hospital for Neurology and Neurosurgery · GBSahlgrenska University Hospital · SEUniversity of California, San Diego · USVA San Diego Healthcare System · US

Funding

UCSD Shiley-Marcos Alzheimer's Disease Research Center P30P30AG062429 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Steven Dyal Edland · 2019 to 2026
$34.9M
AD Strategic Fund ADSF-21-831376-CAlzheimer's Association ZEN-18-533290Alzheimer’s Association ADSF-21-831377-CAlzheimer’s Association ADSF-21-831381-CAlzheimer's Drug Discovery Foundation 20161205Alzheimer's Drug Discovery Foundation 201809-2016862Alzheimer's Society AS-CTF-16b-007Deutsche Forschungsgemeinschaft DFG ME 4858/1-1European Research Council 681712European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 860197Medical Faculty of Tuebingen University 459-0-0Medical Research Council G0400713Medical Research Council MC_UU_00024/1Medical Research Council MC_UU_00024/9NIA NIH HHS P30 AG062429Stiftelsen för Gamla Tjänarinnor FO2019-0228Swedish Research Council #2018-02532
6 · The paper itself

Abstract

This study investigates the diagnostic and prognostic potential of different forms of tau in biofluids from patients with Creutzfeldt-Jakob disease (CJD). Extracellular tau, which is molecularly heterogeneous, was measured using ultra-sensitive custom-made Simoa assays for N-terminal (NT1), mid-region, and full-length tau. We assessed cross-sectional CSF and plasma from healthy controls, patients with Alzheimer's disease (AD) and CJD patients. Then, we evaluated the correlation of the best-performing tau assay (NT1-tau) with clinical severity and functional decline (using the MRC Prion Disease Rating Scale) in a longitudinal CJD cohort (

Indexed as

AdultAgedAged, 80 and overAlzheimer DiseaseBiomarkersCreutzfeldt-Jakob SyndromeDisease ProgressionFemaleHumansImmunoassayMaleMiddle AgedNeurodegenerative DiseasesNeurofilament Proteinstau ProteinsBiomarkersneurofilament protein LNeurofilament Proteinstau ProteinsAlzheimer’s diseasebiomarkerbloodcerebrospinal fluidneurodegenerationneurofilament light chainprion diseaseSimoa-immunoassays

Identifiers

PMID34944022
PMCPMC8700417
OpenAlexW4200058893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.